טוען...
A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
As mesothelin is overexpressed in various types of cancer, it is an attractive target for therapeutic antibodies. T-cell bispecific antibodies bind to target cells and engage T cells via binding to CD3, resulting in target cell killing by T-cell activation. However, the affinity of the CD3-binding a...
שמור ב:
| הוצא לאור ב: | Biomolecules |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7175222/ https://ncbi.nlm.nih.gov/pubmed/32143496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom10030399 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|